FDA Warns of Lunesta Causing Next-Day Impairment – Reports Drugs.com

FDA just issued a warning to healthcare professionals that Lunesta can cause lingering effects resulting in next-day impairment.  The FDA has recommended that doctors advise patients to decrease their starting dose of Lunesta to 1 mg at bedtime.  Both women and men have been reported to be equally effected. The previous recommended dosage of Lunesta was 3 mg which was found to possibly effect a patients driving skills, memory,  and coordination up to eleven hours after taking a nightly dose.

To read the entire article from Drugs.com click here: http://www.drugs.com/fda/eszopiclone-containing-sleep-aids-safety-communication-can-cause-next-day-impairment-13545.html?utm_source=ddc&utm_medium=email&utm_campaign=FDA+Alert+-+Drug+Safety+Communication%3A+Eszopiclone+Containing+Sleep+Aids+-+Can+Cause+Next-Day+Impairment

To read the FDA’s Safety Announcement click here: http://www.fda.gov/Drugs/DrugSafety/ucm397260.htm

 

Nathan T. Williams, Attorney at Law

TheWilliamsLitigationGroup.com

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s